In vitro and in vivo investigations on the antitumour activity of Chelidonium majus

I. Rica Capistrano, An Wouters, Filip Lardon, Claudia Gravekamp, Sandra Apers, Luc Pieters

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background Chelidonium majus L. (Papaveraceae) (greater celandine) is a medicinal herb that is widely spread in Europe. Antitumoural activity has been reported for C. majus extracts. Hypothesis/Purpose To investigate the antitumour activity of a C. majus extract in vitro and in vivo. Study Design Cytotoxic effects of C. majus extracts were evaluated on human cancer cell lines, i.e. PANC-1 (pancreas cancer), HT-29 (colon cancer), MDA-MB-231 (breast cancer), PC-EM005 and PC-EM002 (primary endometrium cancer cells), and PANC02 (murine pancreatic adenocarcinoma cells). A preliminary in vivo study was performed to evaluate the effect of a defatted C. majus extract and UkrainTM in a highly metastatic murine pancreatic model. Methods Chelidonium majus L. herb containing 1.26% (dry weight) of total alkaloids expressed as chelidonine was used to prepare an 80% ethanolic extract (CM2). This crude extract was then defatted with n-hexane, resulting in a defatted C. majus extract (CM2B). Cytotoxic effects of the two extracts (CM2 and CM2B) were evaluated on human and murine cell lines in vitro. CM2B and UkrainTM were evaluated in a highly metastatic murine pancreatic model. Results Four main benzylisoquinoline alkaloids were identified in CM2B, i.e. chelidonine, sanguinarine, chelerythrine and protopine, using HPLC-UV. CM2 showed a high cytotoxic activity against PANC-1 (IC50, 20.7 μg/ml) and HT-29 (IC50, 20.6 μg/ml), and a moderate cytotoxic activity against MDA-MB-231 (IC50, 73.9 μg/ml). CM2 as well as CM2B showed a moderate to high cytotoxic activity against the PANC02 cell line (IC50, 34.4 and 36.0 μg/ml). Low to almost no cytotoxic effect was observed on primary endometrium cancer cells PC-EM005, PC-EM002 and on normal fibroblast cells 3T3, when treated with CM2B. Significantly less metastases were counted in mice treated with 1.2 mg/kg CM2B, but not with 3.6 mg/kg UkrainTM, compared to the control group. The extract, however, did not affect the weight of the primary tumours.

Original languageEnglish (US)
Pages (from-to)1279-1287
Number of pages9
JournalPhytomedicine
Volume22
Issue number14
DOIs
StatePublished - Dec 15 2015

Fingerprint

Chelidonium
Inhibitory Concentration 50
Endometrial Neoplasms
Alkaloids
Cell Line
Papaveraceae
Benzylisoquinolines
3T3 Cells
Medicinal Plants
Tumor Burden
Complex Mixtures
Pancreatic Neoplasms
Colonic Neoplasms
Adenocarcinoma
Fibroblasts
High Pressure Liquid Chromatography
Breast Neoplasms
Neoplasm Metastasis
Weights and Measures
Control Groups

Keywords

  • Chelidonium majus L.
  • Greater celandine
  • In vitro cytotoxicity
  • In vivo antitumor activity
  • Papaveraceae

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Pharmaceutical Science
  • Complementary and alternative medicine
  • Molecular Medicine

Cite this

In vitro and in vivo investigations on the antitumour activity of Chelidonium majus. / Rica Capistrano, I.; Wouters, An; Lardon, Filip; Gravekamp, Claudia; Apers, Sandra; Pieters, Luc.

In: Phytomedicine, Vol. 22, No. 14, 15.12.2015, p. 1279-1287.

Research output: Contribution to journalArticle

Rica Capistrano, I, Wouters, A, Lardon, F, Gravekamp, C, Apers, S & Pieters, L 2015, 'In vitro and in vivo investigations on the antitumour activity of Chelidonium majus', Phytomedicine, vol. 22, no. 14, pp. 1279-1287. https://doi.org/10.1016/j.phymed.2015.10.013
Rica Capistrano, I. ; Wouters, An ; Lardon, Filip ; Gravekamp, Claudia ; Apers, Sandra ; Pieters, Luc. / In vitro and in vivo investigations on the antitumour activity of Chelidonium majus. In: Phytomedicine. 2015 ; Vol. 22, No. 14. pp. 1279-1287.
@article{32e9d6b489574dfca912840847215d20,
title = "In vitro and in vivo investigations on the antitumour activity of Chelidonium majus",
abstract = "Background Chelidonium majus L. (Papaveraceae) (greater celandine) is a medicinal herb that is widely spread in Europe. Antitumoural activity has been reported for C. majus extracts. Hypothesis/Purpose To investigate the antitumour activity of a C. majus extract in vitro and in vivo. Study Design Cytotoxic effects of C. majus extracts were evaluated on human cancer cell lines, i.e. PANC-1 (pancreas cancer), HT-29 (colon cancer), MDA-MB-231 (breast cancer), PC-EM005 and PC-EM002 (primary endometrium cancer cells), and PANC02 (murine pancreatic adenocarcinoma cells). A preliminary in vivo study was performed to evaluate the effect of a defatted C. majus extract and UkrainTM in a highly metastatic murine pancreatic model. Methods Chelidonium majus L. herb containing 1.26{\%} (dry weight) of total alkaloids expressed as chelidonine was used to prepare an 80{\%} ethanolic extract (CM2). This crude extract was then defatted with n-hexane, resulting in a defatted C. majus extract (CM2B). Cytotoxic effects of the two extracts (CM2 and CM2B) were evaluated on human and murine cell lines in vitro. CM2B and UkrainTM were evaluated in a highly metastatic murine pancreatic model. Results Four main benzylisoquinoline alkaloids were identified in CM2B, i.e. chelidonine, sanguinarine, chelerythrine and protopine, using HPLC-UV. CM2 showed a high cytotoxic activity against PANC-1 (IC50, 20.7 μg/ml) and HT-29 (IC50, 20.6 μg/ml), and a moderate cytotoxic activity against MDA-MB-231 (IC50, 73.9 μg/ml). CM2 as well as CM2B showed a moderate to high cytotoxic activity against the PANC02 cell line (IC50, 34.4 and 36.0 μg/ml). Low to almost no cytotoxic effect was observed on primary endometrium cancer cells PC-EM005, PC-EM002 and on normal fibroblast cells 3T3, when treated with CM2B. Significantly less metastases were counted in mice treated with 1.2 mg/kg CM2B, but not with 3.6 mg/kg UkrainTM, compared to the control group. The extract, however, did not affect the weight of the primary tumours.",
keywords = "Chelidonium majus L., Greater celandine, In vitro cytotoxicity, In vivo antitumor activity, Papaveraceae",
author = "{Rica Capistrano}, I. and An Wouters and Filip Lardon and Claudia Gravekamp and Sandra Apers and Luc Pieters",
year = "2015",
month = "12",
day = "15",
doi = "10.1016/j.phymed.2015.10.013",
language = "English (US)",
volume = "22",
pages = "1279--1287",
journal = "Phytomedicine",
issn = "0944-7113",
publisher = "Urban und Fischer Verlag Jena",
number = "14",

}

TY - JOUR

T1 - In vitro and in vivo investigations on the antitumour activity of Chelidonium majus

AU - Rica Capistrano, I.

AU - Wouters, An

AU - Lardon, Filip

AU - Gravekamp, Claudia

AU - Apers, Sandra

AU - Pieters, Luc

PY - 2015/12/15

Y1 - 2015/12/15

N2 - Background Chelidonium majus L. (Papaveraceae) (greater celandine) is a medicinal herb that is widely spread in Europe. Antitumoural activity has been reported for C. majus extracts. Hypothesis/Purpose To investigate the antitumour activity of a C. majus extract in vitro and in vivo. Study Design Cytotoxic effects of C. majus extracts were evaluated on human cancer cell lines, i.e. PANC-1 (pancreas cancer), HT-29 (colon cancer), MDA-MB-231 (breast cancer), PC-EM005 and PC-EM002 (primary endometrium cancer cells), and PANC02 (murine pancreatic adenocarcinoma cells). A preliminary in vivo study was performed to evaluate the effect of a defatted C. majus extract and UkrainTM in a highly metastatic murine pancreatic model. Methods Chelidonium majus L. herb containing 1.26% (dry weight) of total alkaloids expressed as chelidonine was used to prepare an 80% ethanolic extract (CM2). This crude extract was then defatted with n-hexane, resulting in a defatted C. majus extract (CM2B). Cytotoxic effects of the two extracts (CM2 and CM2B) were evaluated on human and murine cell lines in vitro. CM2B and UkrainTM were evaluated in a highly metastatic murine pancreatic model. Results Four main benzylisoquinoline alkaloids were identified in CM2B, i.e. chelidonine, sanguinarine, chelerythrine and protopine, using HPLC-UV. CM2 showed a high cytotoxic activity against PANC-1 (IC50, 20.7 μg/ml) and HT-29 (IC50, 20.6 μg/ml), and a moderate cytotoxic activity against MDA-MB-231 (IC50, 73.9 μg/ml). CM2 as well as CM2B showed a moderate to high cytotoxic activity against the PANC02 cell line (IC50, 34.4 and 36.0 μg/ml). Low to almost no cytotoxic effect was observed on primary endometrium cancer cells PC-EM005, PC-EM002 and on normal fibroblast cells 3T3, when treated with CM2B. Significantly less metastases were counted in mice treated with 1.2 mg/kg CM2B, but not with 3.6 mg/kg UkrainTM, compared to the control group. The extract, however, did not affect the weight of the primary tumours.

AB - Background Chelidonium majus L. (Papaveraceae) (greater celandine) is a medicinal herb that is widely spread in Europe. Antitumoural activity has been reported for C. majus extracts. Hypothesis/Purpose To investigate the antitumour activity of a C. majus extract in vitro and in vivo. Study Design Cytotoxic effects of C. majus extracts were evaluated on human cancer cell lines, i.e. PANC-1 (pancreas cancer), HT-29 (colon cancer), MDA-MB-231 (breast cancer), PC-EM005 and PC-EM002 (primary endometrium cancer cells), and PANC02 (murine pancreatic adenocarcinoma cells). A preliminary in vivo study was performed to evaluate the effect of a defatted C. majus extract and UkrainTM in a highly metastatic murine pancreatic model. Methods Chelidonium majus L. herb containing 1.26% (dry weight) of total alkaloids expressed as chelidonine was used to prepare an 80% ethanolic extract (CM2). This crude extract was then defatted with n-hexane, resulting in a defatted C. majus extract (CM2B). Cytotoxic effects of the two extracts (CM2 and CM2B) were evaluated on human and murine cell lines in vitro. CM2B and UkrainTM were evaluated in a highly metastatic murine pancreatic model. Results Four main benzylisoquinoline alkaloids were identified in CM2B, i.e. chelidonine, sanguinarine, chelerythrine and protopine, using HPLC-UV. CM2 showed a high cytotoxic activity against PANC-1 (IC50, 20.7 μg/ml) and HT-29 (IC50, 20.6 μg/ml), and a moderate cytotoxic activity against MDA-MB-231 (IC50, 73.9 μg/ml). CM2 as well as CM2B showed a moderate to high cytotoxic activity against the PANC02 cell line (IC50, 34.4 and 36.0 μg/ml). Low to almost no cytotoxic effect was observed on primary endometrium cancer cells PC-EM005, PC-EM002 and on normal fibroblast cells 3T3, when treated with CM2B. Significantly less metastases were counted in mice treated with 1.2 mg/kg CM2B, but not with 3.6 mg/kg UkrainTM, compared to the control group. The extract, however, did not affect the weight of the primary tumours.

KW - Chelidonium majus L.

KW - Greater celandine

KW - In vitro cytotoxicity

KW - In vivo antitumor activity

KW - Papaveraceae

UR - http://www.scopus.com/inward/record.url?scp=84949526560&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949526560&partnerID=8YFLogxK

U2 - 10.1016/j.phymed.2015.10.013

DO - 10.1016/j.phymed.2015.10.013

M3 - Article

C2 - 26626193

AN - SCOPUS:84949526560

VL - 22

SP - 1279

EP - 1287

JO - Phytomedicine

JF - Phytomedicine

SN - 0944-7113

IS - 14

ER -